Combination of a high bolus dose of tirofiban with half-dose thrombolytics for the treatment of subacute stent thrombosis

Acute stent thrombosis is rare and it is usually related to complications during the procedure. Subacute thrombosis is far more common and is associated with a high incidence of acute myocardial infarction and death. Restoration of flow by thrombolysis, emergency bypass surgery or emergency percutaneous transluminal coronary angioplasty (PTCA) has had only limited success with respect to myocardial salvage. We report the case of a patient who suffered from recurrent subacute stent thrombosis, in whom administration of tirofiban at high-dose bolus in association with a half dose of recombinant tissue plasminogen activator succeeded in restoring normal myocardial flow and stable clinical condition.

[1]  N. Lakkis,et al.  Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban. , 2003, The American journal of cardiology.

[2]  R. Baglini,et al.  Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention , 2003, Current medical research and opinion.

[3]  N. Lakkis,et al.  Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. , 2002, The American journal of cardiology.

[4]  S. Pocock,et al.  A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .

[5]  C. Macaya,et al.  Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). , 1998, Circulation.

[6]  E. Fleck,et al.  Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. , 1998, Circulation.

[7]  M. Hadamitzky,et al.  Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. , 1997, Circulation.

[8]  M. Bell,et al.  Coronary angioplasty and intracoronary thrombolysis are of limited efficacy in resolving early intracoronary stent thrombosis. , 1996, Journal of the American College of Cardiology.

[9]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[10]  S. Ellis,et al.  Subacute stent thrombosis: evolving issues and current concepts. , 1996, Journal of the American College of Cardiology.